Dotfix2 mg

Dotfix is a selective urate reabsorption inhibitor (URAT1 inhibitor) used for lowering elevated serum uric acid levels. Its evidence-based uses include:

• Established/labeled use: Treatment of hyperuricemia associated with gout, to reduce serum uric acid and decrease the frequency of gouty arthritis flares.
• Established/labeled use: Long-term management of chronic gout, including tophaceous gout, as part of urate-lowering therapy.
• Guideline-supported use: As an alternative urate-lowering agent in patients who are intolerant of, or have an inadequate response to, xanthine oxidase inhibitors (e.g., allopurinol, febuxostat), used either as monotherapy or in combination with a xanthine oxidase inhibitor.

Dotfix is not indicated for treating acute gout flares themselves; it is used for chronic urate-lowering therapy and should not be started during an acute attack (see Precautions and Warnings).

Each tablet of Dotinurad contains Dotinurad INN as the active ingredient, commonly available in strengths of 0.5 mg, 1 mg, and 2 mg for oral administration.

Dotfix is a relatively newer oral medication belonging to the class of selective urate reabsorption inhibitors (URAT1 inhibitors), developed for long-term management of hyperuricemia in patients with gout. Unlike xanthine oxidase inhibitors, which reduce uric acid production, Dotfix works by promoting renal excretion of uric acid through selective inhibition of the URAT1 transporter, while sparing other renal urate transporters such as ABCG2, OAT1, and OAT3.

Dotfix is available as tablets in strengths of 0.5 mg, 1 mg, and 2 mg. As a comparatively new drug class, long-term safety data remain more limited than for older, well-established urate-lowering agents.

Dotfix belongs to the therapeutic class of Antigout Agents, specifically the subclass of Selective Urate Reabsorption Inhibitors (URAT1 Inhibitors), a uricosuric drug class distinct from xanthine oxidase inhibitors (e.g., allopurinol, febuxostat) and older uricosurics such as probenecid or benzbromarone.

Dotinurad lowers serum uric acid by selectively inhibiting the urate transporter 1 (URAT1/SLC22A12) located on the apical membrane of renal proximal tubular cells. URAT1 is the principal transporter responsible for reabsorbing filtered and secreted uric acid back into the bloodstream. By selectively blocking URAT1, Dotinurad reduces tubular reabsorption of uric acid, thereby increasing its urinary excretion and lowering serum urate concentrations.

A key pharmacological feature of Dotinurad is its selectivity for URAT1 over other urate/organic anion transporters such as ABCG2, OAT1, and OAT3, which are involved in intestinal and alternative renal excretion pathways. This selectivity is proposed to reduce the risk of interactions and off-target effects compared with less selective uricosuric agents.

Peak plasma concentrations of Dotinurad are reached within a few hours of oral dosing, and the drug is primarily metabolized hepatically with renal and biliary elimination of metabolites.

Dotfix tablets are for oral use only. They may be swallowed whole with a glass of water, with or without food, once daily at a consistent time to support treatment adherence. Adequate fluid intake is recommended while taking Dotfix to reduce the risk of uric acid crystal formation in the urinary tract. If a dose of Dotfix is missed, it should be taken as soon as remembered unless it is close to the time of the next dose, in which case the missed dose should be skipped; doses should never be doubled.

Dotfix has the following clinically significant interactions:

• Pyrazinamide: May antagonize the uricosuric effect of Dotfix by promoting uric acid retention, potentially reducing its effectiveness.
• Salicylates (e.g., aspirin), especially at higher/anti-inflammatory doses: May reduce the uricosuric effect of Dotfix by interfering with renal uric acid excretion; low-dose aspirin used for cardiovascular protection is generally considered to have a lesser effect but should still be used with medical guidance.
• Other uricosuric or urate-lowering agents: Concurrent use with other drugs affecting uric acid handling should be supervised by a physician to avoid additive effects or reduced efficacy.

Patients should inform their physician of all medications, supplements, and herbal products being used before starting Dotfix.

The following adverse effects have been reported with Dotfix:

Patients should seek prompt medical attention for signs of severe hypersensitivity, significant flank pain or blood in the urine (possible urolithiasis), or jaundice while taking Dotfix.

Data on the use of Dotfix in human pregnancy are limited. Dotfix should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision.

Dotfix or its metabolites may pass into breast milk. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue Dotfix, taking into account the importance of the drug to the mother.

The following precautions apply to the use of Dotfix:

• Renal impairment: Efficacy of Dotfix may be reduced in patients with impaired renal function; use with caution and monitor renal function periodically. Dotfix is contraindicated in severe renal impairment or dialysis (see Contraindications).
• Urolithiasis risk: As a uricosuric agent, Dotfix increases urinary uric acid excretion, which may increase the risk of uric acid urinary stone formation. Adequate hydration (increased fluid intake) is recommended throughout treatment, and urine alkalinization may be considered by the physician if indicated. Use with particular caution in patients with a history of urolithiasis.
• Hepatic monitoring: Periodic monitoring of liver function is recommended during treatment with Dotfix, as elevated liver enzymes have been reported.
• Acute gout flare: Do not initiate Dotfix during an acute gout attack, as urate-lowering therapy can transiently worsen flares. If a flare develops during established treatment, therapy may generally be continued alongside appropriate anti-inflammatory management.
• Limited long-term data: Dotfix belongs to a relatively newer drug class (URAT1 inhibitors), and long-term safety data are more limited compared with older, well-established urate-lowering agents; ongoing clinical monitoring is advised.

Limited specific data exist on overdose with Dotfix. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Management should be supportive and symptomatic, with monitoring of renal function and general clinical status under medical supervision; there is no specific antidote for Dotfix overdose.

Store Dotfix at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Dotfix may be used in elderly patients with appropriate monitoring of renal function, as this population is more likely to have age-related decline in renal function.

Renal impairment: Use with caution in mild-to-moderate renal impairment due to potentially reduced efficacy; Dotfix is contraindicated in severe renal impairment and dialysis patients (see Contraindications).

Hepatic impairment: Use with caution and monitor liver function, as data in significant hepatic impairment are limited.

Pediatric patients: Safety and efficacy of Dotfix have not been established in children and adolescents; use is not recommended in this population.

Treatment with Dotfix for chronic hyperuricemia and gout is typically long-term/ongoing, as urate-lowering therapy is generally continued indefinitely to maintain target serum uric acid levels and prevent recurrent gout flares, unless discontinued by a physician due to adverse effects, lack of efficacy, or resolution of the underlying condition. The duration should always be determined by the treating physician based on individual response and monitoring.

Antigout Agents > Uricosuric Agents > Selective Urate Reabsorption Inhibitors (URAT1 Inhibitors)

Dotinurad acts by selectively inhibiting the URAT1 (SLC22A12) urate transporter on renal proximal tubule cells, blocking reabsorption of uric acid back into the blood and thereby increasing its excretion in urine, which lowers serum uric acid levels. Its selectivity for URAT1 over other transporters such as ABCG2, OAT1, and OAT3 distinguishes Dotinurad from older, less selective uricosuric agents.

The safety and efficacy of Dotfix have not been established in pediatric patients. Dotfix is not recommended for use in children and adolescents until further clinical data become available.